Should Pfizer Shareholders Sell Their Viatris Stock?
Pfizer's (NYSE: PFE) long-awaited deal is finally done. Last week, the big drugmaker completed its merger of Upjohn with Mylan. The transaction created a new entity, Viatris (NASDAQ: VTRS), that's a leader in branded and generic drugs and biosimilars.
If you owned Pfizer shares prior to the close of the deal, you now also own roughly 0.124079 shares of Viatris for every one share of Pfizer common stock held. Should Pfizer shareholders sell their Viatris stock? Or does holding make more sense for now?
Image source: Getty Images.
Source Fool.com
